Galectin-3與腫瘤轉移_《中國普外基礎與臨床雜志》

作者：

楊志明 , 伍曉汀 , 何濤

四川大學華西醫院普外科（成都610041）;

關鍵詞：

Galectin-3 腫瘤轉移

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

【摘要】目的研究galectin-3與腫瘤轉移的關系及其臨床應用前景。
方法對相關文獻進行綜述分析。
結果Galectin-3是β-半乳糖凝集素的成員之一，在上皮細胞和免疫細胞中廣泛表達，與細胞內糖蛋白、細胞表面分子和細胞外基質蛋白相互作用，表現出各種生物學特性，包括細胞的生長、黏附、血管形成以及凋亡，且與腫瘤的侵襲、轉移密切相關。
結論基于與腫瘤侵襲、轉移的相關性，galectin-3有可能作為一種可靠的腫瘤轉移的診斷標記物及癌癥治療的靶向蛋白之一。

引用本文： 楊志明,伍曉汀,何濤. Galectin-3與腫瘤轉移. 中國普外基礎與臨床雜志, 2005, 12(3): 310-313. doi: 復制

1.	Liu FT, Hsu DK, Zuberi RI, et al. Expression and function of galectin3, a betagalactosidebinding lectin, in human monocytes and macrophages [J]. Am J Pathol, 1995; 147(4)∶1016.
2.	Lotan R, Ito H, Yasui W, et al. Expression of a 31kDa lactosidebinding lectin in normal human gastric mucosa and in primary and metastatic gastric carcinomas [J]. Int J Cancer, 1994; 56(4)∶474.
3.	Nagy N, Legendre H, Engels O, et al. Refined prognostic evaluation in colon carcinoma using immunohistochemical galectin fingerprinting [J]. Cancer, 2003; 97(8)∶1849.
4.	Schoeppner HL, Raz A, Ho SB, et al. Expression of an endogenous galactosebinding lectin correlates with neoplastic progression in the colon [J]. Cancer, 1995; 75(12)∶2818.
5.	O’Driscoll L, Linehan R, MKennedy S, et al. Lack of prognostic significance of survivin, survivindeltaEx3, survivin2B, galectin3, bag1, baxalpha and MRP1 mRNAs in breast cancer [J]. Cancer Lett, 2003; 201(2)∶225.
6.	Ellerhorst JA, Stephens LC, Nguyen T, et al. Effects of galectin3 expression on growth and tumorigenicity of the prostate cancer cell line LNCaP [J]. Prostate, 2002; 50(1)∶64.
7.	Konstantinov KN, Robbins BA, Liu FT. Galectin3, a betagalactosidebinding animal lectin, is a marker of anaplastic largecell lymphoma [J]. Am J Pathol, 1996; 148(1)∶25.
8.	Xu XC, elNaggar AK, Lotan R. Differential expression of galectin1 and galectin3 in thyroid tumors. Potential diagnostic implications [J]. Am J Pathol, 1995; 147(3)∶815.
9.	van den Brule FA, Buicu C, Berchuck A, et al. Expression of the 67kD laminin receptor, galectin1, and galectin3 in advanced human uterine adenocarcinoma [J]. Hum Pathol, 1996; 27(11)∶1185.
10.	Mollenhauer J, Deichmann M, Helmke B, et al. Frequent downregulation of DMBT1 and galectin3 in epithelial skin cancer [J]. Int J Cancer, 2003; 105(2)∶149.
11.	Gillenwater A, Xu XC, elNaggar AK, et al. Expression of galectins in head and neck squamous cell carcinoma [J]. Head Neck, 1996; 18(5)∶422.
12.	Baldus SE, Zirbes TK, Weingarten M, et al. Increased galectin3 expression in gastric cancer: correlations with histopathological subtypes, galactosylated antigens and tumor cell proliferation [J]. Tumour Biol, 2000; 21(5)∶258.
13.	Woo HJ, Joo HG, Song SW, et al. Immunohistochemical detection of galectin3 in canine gastric carcinomas [J]. J Comp Pathol, 2001; 124(2-3)∶216.
14.	Barondes SH, Cooper DN, Gitt MA, et al. Galectins. Structure and function of a large family of animal lectins [J]. J Biol Chem, 1994;269(33)∶20807.
15.	Gong HC, Honjo Y, NangiaMakker P, et al. The NH2 terminus of galectin3 governs cellular compartmentalization and functions in cancer cells [J]. Cancer Res, 1999; 59(24)∶6239.
16.	Herrmann J, Turck CW, Atchison RE, et al. Primary structure of the soluble lactose binding lectin L29 from rat and dog and interaction of its noncollagenous proline, glycine, tyrosinerich sequence with bacterial and tissue collagenase [J]. J Biol Chem, 1993; 268(35)∶26704.
17.	Kohn EC. Development and prevention of metastasis [J]. Anticancer Res, 1993; 13(6B)∶2553.
18.	Raz A, Lotan R. Endogenous galactosidebinding lectins: a new class of functional tumor cell surface molecules related to metastasis [J]. Cancer Metastasis Rev, 1987; 6(3)∶433.
19.	Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease [J]. Nat Med, 1995; 1(1)∶27.
20.	NangiaMakker P, Baccarini S, Raz A. Carbohydraterecognition and angiogenesis [J]. Cancer Metastasis Rev, 2000; 19(1-2)∶51.
21.	Moiseeva EP, Javed Q, Spring EL, et al. Galectin 1 is involved in vascular smooth muscle cell proliferation [J]. Cardiovasc Res, 2000; 45(2)∶493.
22.	NangiaMakker P, Honjo Y, Sarvis R, et al. Galectin3 induces endothelial cell morphogenesis and angiogenesis [J]. Am J Pathol, 2000; 156(3)∶899.
23.	Woo HJ, Shaw LM, Messier JM, et al. The major nonintegrin laminin binding protein of macrophages is identical to carbohydrate binding protein 35 (Mac2) [J]. J Biol Chem, 1990; 265(13)∶7097.
24.	Parise LV, Lee J, Juliano RL. New aspects of integrin signaling in cancer [J]. Semin Cancer Biol, 2000; 10(6)∶407.
25.	Matarrese P, Fusco O, Tinari N, et al. Galectin3 overexpression protects from apoptosis by improving cell adhesion properties [J]. Int J Cancer, 2000; 85(4)∶545.
26.	Warfield PR, Makker PN, Raz A, et al. Adhesion of human breast carcinoma to extracellular matrix proteins is modulated by galectin3 [J]. Invasion Metastasis, 1997; 17(2)∶101.
27.	Ochieng J, Fridman R, NangiaMakker P, et al. Galectin3 is a novel substrate for human matrix metalloproteinases2 and 9 [J]. Biochemistry, 1994; 33(47)∶14109.
28.	Zucker S, Cao J, Chen WT. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment [J]. Oncogene, 2000; 19(56)∶6642.
29.	Raz A, Bucana C, McLellan W, et al. Distribution of membrane anionic sites on B16 melanoma variants with differing lung colonising potential [J]. Nature, 1980; 284(5754)∶363.
30.	Inohara H, Akahani S, Koths K, et al. Interactions between galectin3 and Mac2binding protein mediate cellcell adhesion [J]. Cancer Res, 1996; 56(19)∶4530.
31.	Glinsky VV, Huflejt ME, Glinsky GV, et al. Effects of ThomsenFriedenreich antigenspecific peptide P30 on betagalactosidemediated homotypic aggregation and adhesion to the endothelium of MDAMB435 human breast carcinoma cells [J]. Cancer Res, 2000; 60(10)∶2584.
32.	Glinsky VV, Glinsky GV, RittenhouseOlson K, et al. The role of ThomsenFriedenreich antigen in adhesion of human breast and prostate cancer cells to the endothelium [J]. Cancer Res, 2001; 61(12)∶4851.
33.	Mareel MM, Crombez R. Biology of cancer invasion and metastasis [J]. Acta Otorhinolaryngol Belg, 1992; 46(2)∶107.
34.	Zhu Z, SanchezSweatman O, Huang X, et al. Anoikis and metastatic potential of cloudman S91 melanoma cells [J]. Cancer Res, 2001; 61(4)∶1707.
35.	Kim HR, Lin HM, Biliran H, et al. Cell cycle arrest and inhibition of anoikis by galectin3 in human breast epithelial cells [J]. Cancer Res, 1999; 59(16)∶4148.
36.	Yoshii T, Fukumori T, Honjo Y, et al. Galectin3 phosphorylation is required for its antiapoptotic function and cell cycle arrest [J]. J Biol Chem, 2002; 277(9)∶6852.
37.	Akahani S, NangiaMakker P, Inohara H, et al. Galectin3： a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl2 family [J]. Cancer Res, 1997; 57(23)∶5272.
38.	Iurisci I, Tinari N, Natoli C, et al. Concentrations of galectin3 in the sera of normal controls and cancer patients [J]. Clin Cancer Res, 2000; 6(4)∶1389.
39.	Platt D, Raz A. Modulation of the lung colonization of B16F1 melanoma cells by citrus pectin [J]. J Natl Cancer Inst, 1992; 84(6)∶438.
40.	NangiaMakker P, Honjo Y, Sarvis R, et al. Galectin3 induces endothelial cell morphogenesis and angiogenesis [J]. Am J Pathol, 2000; 156(3)∶899.
41.	NangiaMakker P, Hogan V, Honjo Y, et al. Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin [J]. J Natl Cancer Inst, 2002; 94(24)∶1854.
42.	Pienta KJ, Naik H, Akhtar A, et al. Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin [J]. J Natl Cancer Inst, 1995; 87(5)∶348.
43.	Colnot C, Fowlis D, Ripoche MA, et al. Embryonic implantation in galectin 1/galectin 3 double mutant mice [J]. Dev Dyn, 1998; 211(4)∶306.

1. Liu FT, Hsu DK, Zuberi RI, et al. Expression and function of galectin3, a betagalactosidebinding lectin, in human monocytes and macrophages [J]. Am J Pathol, 1995; 147(4)∶1016.
2. Lotan R, Ito H, Yasui W, et al. Expression of a 31kDa lactosidebinding lectin in normal human gastric mucosa and in primary and metastatic gastric carcinomas [J]. Int J Cancer, 1994; 56(4)∶474.
3. Nagy N, Legendre H, Engels O, et al. Refined prognostic evaluation in colon carcinoma using immunohistochemical galectin fingerprinting [J]. Cancer, 2003; 97(8)∶1849.
4. Schoeppner HL, Raz A, Ho SB, et al. Expression of an endogenous galactosebinding lectin correlates with neoplastic progression in the colon [J]. Cancer, 1995; 75(12)∶2818.
5. O’Driscoll L, Linehan R, MKennedy S, et al. Lack of prognostic significance of survivin, survivindeltaEx3, survivin2B, galectin3, bag1, baxalpha and MRP1 mRNAs in breast cancer [J]. Cancer Lett, 2003; 201(2)∶225.
6. Ellerhorst JA, Stephens LC, Nguyen T, et al. Effects of galectin3 expression on growth and tumorigenicity of the prostate cancer cell line LNCaP [J]. Prostate, 2002; 50(1)∶64.
7. Konstantinov KN, Robbins BA, Liu FT. Galectin3, a betagalactosidebinding animal lectin, is a marker of anaplastic largecell lymphoma [J]. Am J Pathol, 1996; 148(1)∶25.
8. Xu XC, elNaggar AK, Lotan R. Differential expression of galectin1 and galectin3 in thyroid tumors. Potential diagnostic implications [J]. Am J Pathol, 1995; 147(3)∶815.
9. van den Brule FA, Buicu C, Berchuck A, et al. Expression of the 67kD laminin receptor, galectin1, and galectin3 in advanced human uterine adenocarcinoma [J]. Hum Pathol, 1996; 27(11)∶1185.
10. Mollenhauer J, Deichmann M, Helmke B, et al. Frequent downregulation of DMBT1 and galectin3 in epithelial skin cancer [J]. Int J Cancer, 2003; 105(2)∶149.
11. Gillenwater A, Xu XC, elNaggar AK, et al. Expression of galectins in head and neck squamous cell carcinoma [J]. Head Neck, 1996; 18(5)∶422.
12. Baldus SE, Zirbes TK, Weingarten M, et al. Increased galectin3 expression in gastric cancer: correlations with histopathological subtypes, galactosylated antigens and tumor cell proliferation [J]. Tumour Biol, 2000; 21(5)∶258.
13. Woo HJ, Joo HG, Song SW, et al. Immunohistochemical detection of galectin3 in canine gastric carcinomas [J]. J Comp Pathol, 2001; 124(2-3)∶216.
14. Barondes SH, Cooper DN, Gitt MA, et al. Galectins. Structure and function of a large family of animal lectins [J]. J Biol Chem, 1994;269(33)∶20807.
15. Gong HC, Honjo Y, NangiaMakker P, et al. The NH2 terminus of galectin3 governs cellular compartmentalization and functions in cancer cells [J]. Cancer Res, 1999; 59(24)∶6239.
16. Herrmann J, Turck CW, Atchison RE, et al. Primary structure of the soluble lactose binding lectin L29 from rat and dog and interaction of its noncollagenous proline, glycine, tyrosinerich sequence with bacterial and tissue collagenase [J]. J Biol Chem, 1993; 268(35)∶26704.
17. Kohn EC. Development and prevention of metastasis [J]. Anticancer Res, 1993; 13(6B)∶2553.
18. Raz A, Lotan R. Endogenous galactosidebinding lectins: a new class of functional tumor cell surface molecules related to metastasis [J]. Cancer Metastasis Rev, 1987; 6(3)∶433.
19. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease [J]. Nat Med, 1995; 1(1)∶27.
20. NangiaMakker P, Baccarini S, Raz A. Carbohydraterecognition and angiogenesis [J]. Cancer Metastasis Rev, 2000; 19(1-2)∶51.
21. Moiseeva EP, Javed Q, Spring EL, et al. Galectin 1 is involved in vascular smooth muscle cell proliferation [J]. Cardiovasc Res, 2000; 45(2)∶493.
22. NangiaMakker P, Honjo Y, Sarvis R, et al. Galectin3 induces endothelial cell morphogenesis and angiogenesis [J]. Am J Pathol, 2000; 156(3)∶899.
23. Woo HJ, Shaw LM, Messier JM, et al. The major nonintegrin laminin binding protein of macrophages is identical to carbohydrate binding protein 35 (Mac2) [J]. J Biol Chem, 1990; 265(13)∶7097.
24. Parise LV, Lee J, Juliano RL. New aspects of integrin signaling in cancer [J]. Semin Cancer Biol, 2000; 10(6)∶407.
25. Matarrese P, Fusco O, Tinari N, et al. Galectin3 overexpression protects from apoptosis by improving cell adhesion properties [J]. Int J Cancer, 2000; 85(4)∶545.
26. Warfield PR, Makker PN, Raz A, et al. Adhesion of human breast carcinoma to extracellular matrix proteins is modulated by galectin3 [J]. Invasion Metastasis, 1997; 17(2)∶101.
27. Ochieng J, Fridman R, NangiaMakker P, et al. Galectin3 is a novel substrate for human matrix metalloproteinases2 and 9 [J]. Biochemistry, 1994; 33(47)∶14109.
28. Zucker S, Cao J, Chen WT. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment [J]. Oncogene, 2000; 19(56)∶6642.
29. Raz A, Bucana C, McLellan W, et al. Distribution of membrane anionic sites on B16 melanoma variants with differing lung colonising potential [J]. Nature, 1980; 284(5754)∶363.
30. Inohara H, Akahani S, Koths K, et al. Interactions between galectin3 and Mac2binding protein mediate cellcell adhesion [J]. Cancer Res, 1996; 56(19)∶4530.
31. Glinsky VV, Huflejt ME, Glinsky GV, et al. Effects of ThomsenFriedenreich antigenspecific peptide P30 on betagalactosidemediated homotypic aggregation and adhesion to the endothelium of MDAMB435 human breast carcinoma cells [J]. Cancer Res, 2000; 60(10)∶2584.
32. Glinsky VV, Glinsky GV, RittenhouseOlson K, et al. The role of ThomsenFriedenreich antigen in adhesion of human breast and prostate cancer cells to the endothelium [J]. Cancer Res, 2001; 61(12)∶4851.
33. Mareel MM, Crombez R. Biology of cancer invasion and metastasis [J]. Acta Otorhinolaryngol Belg, 1992; 46(2)∶107.
34. Zhu Z, SanchezSweatman O, Huang X, et al. Anoikis and metastatic potential of cloudman S91 melanoma cells [J]. Cancer Res, 2001; 61(4)∶1707.
35. Kim HR, Lin HM, Biliran H, et al. Cell cycle arrest and inhibition of anoikis by galectin3 in human breast epithelial cells [J]. Cancer Res, 1999; 59(16)∶4148.
36. Yoshii T, Fukumori T, Honjo Y, et al. Galectin3 phosphorylation is required for its antiapoptotic function and cell cycle arrest [J]. J Biol Chem, 2002; 277(9)∶6852.
37. Akahani S, NangiaMakker P, Inohara H, et al. Galectin3： a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl2 family [J]. Cancer Res, 1997; 57(23)∶5272.
38. Iurisci I, Tinari N, Natoli C, et al. Concentrations of galectin3 in the sera of normal controls and cancer patients [J]. Clin Cancer Res, 2000; 6(4)∶1389.
39. Platt D, Raz A. Modulation of the lung colonization of B16F1 melanoma cells by citrus pectin [J]. J Natl Cancer Inst, 1992; 84(6)∶438.
40. NangiaMakker P, Honjo Y, Sarvis R, et al. Galectin3 induces endothelial cell morphogenesis and angiogenesis [J]. Am J Pathol, 2000; 156(3)∶899.
41. NangiaMakker P, Hogan V, Honjo Y, et al. Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin [J]. J Natl Cancer Inst, 2002; 94(24)∶1854.
42. Pienta KJ, Naik H, Akhtar A, et al. Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin [J]. J Natl Cancer Inst, 1995; 87(5)∶348.
43. Colnot C, Fowlis D, Ripoche MA, et al. Embryonic implantation in galectin 1/galectin 3 double mutant mice [J]. Dev Dyn, 1998; 211(4)∶306.

《中國普外基礎與臨床雜志》

Galectin-3與腫瘤轉移

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

《中國普外基礎與臨床雜志》

Galectin-3與腫瘤轉移

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料